Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;20(6):343-344.
doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.

Complement as a target in COVID-19?

Antonio M Risitano  1 , Dimitrios C Mastellos  2 , Markus Huber-Lang  3 , Despina Yancopoulou  4 , Cecilia Garlanda  5   6 , Fabio Ciceri  7 , John D Lambris  8
Affiliations

Complement as a target in COVID-19?

Antonio M Risitano et al. Nat Rev Immunol. 2020 Jun.

Erratum in

  • Author Correction: Complement as a target in COVID-19?
    Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Risitano AM, et al. Nat Rev Immunol. 2020 Jul;20(7):448. doi: 10.1038/s41577-020-0366-6. Nat Rev Immunol. 2020. PMID: 32533108 Free PMC article.

Abstract

There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.

PubMed Disclaimer

Conflict of interest statement

J.D.L. is the founder of Amyndas Pharmaceuticals and inventor of patents related to complement inhibitors, including a technology licensed to Apellis Pharmaceuticals. A.M.R. has received support from or served as an adviser for Biocryst, Achillion, Alexion, Alnylam, Amyndas, Apellis, Novartis, Roche, Omeros, Pfizer, Rapharma, Samsung and Sanofi. M.H.-L. holds a patent relating to C5a inhibition licensed to InflaRx. D.Y. is the Managing Director of Amyndas Pharmaceuticals. D.C.M., C.G. and F.C. declare no competing interests.

Figures

Fig. 1
Fig. 1. Targeting complement in SARS-CoV-2-associated lung injury.
Complement activation may contribute to the maladaptive inflammatory response seen in some patients with severe COVID-19. Inhibition of C3 or C5 may have therapeutic potential. ARDS, acute respiratory distress syndrome.
See this image and copyright information in PMC

References

    1. Guan W-j, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Li G, et al. Coronavirus infections and immune responses. J. Med. Virol. 2020;92:424–432. doi: 10.1002/jmv.25685. - DOI - PMC - PubMed
    1. Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 2018;18:707–729. doi: 10.1038/s41573-019-0031-6. - DOI - PMC - PubMed
    1. Gralinski LE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018 doi: 10.1128/mBio.01753-18. - DOI - PMC - PubMed
    1. Zilow G, et al. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit. Care Med. 1992;20:468–473. doi: 10.1097/00003246-199204000-00006. - DOI - PubMed

MeSH terms

Substances